Aspirin plus dabrafenib and trametinib for BRAF V600E lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding aspirin to the targeted drugs dabrafenib and trametinib can work better for advanced lung cancer that has a specific gene change (BRAF V600E). The goal is to see if the combination helps slow the cancer or shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIB or IV) non-small cell lung cancer that cannot be removed with surgery.
- Your tumor has a specific gene change called BRAF V600E.
- You are planning to take two targeted drugs – dabrafenib and trametinib.
- You are able to take care of yourself (ECOG score 0 or 1).
- Your main tumor is at least 1 cm (about the size of a pea) in diameter.
- You are not taking any other blood-thinning medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted treatment given before and after surgery for people with a specific type of early-stage lung cancer that has a BRAF V600 or MET exon 14 mutation. The goal is to see if the treatment helps shrink the tumor before surgery and prevent it from coming back afterward.
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
This Phase 2 trial tests a targeted treatment for adults with papillary craniopharyngioma that has a specific BRAF change (V600E). It may help shrink or control the tumor, especially when surgery is not expected to remove it safely.
This trial tests cetuximab combined with dabrafenib and tislelizumab in people with advanced colorectal cancer that has a BRAF V600E mutation. It’s for cases where the first standard treatment didn’t work or couldn’t be tolerated, aiming to shrink tumors and improve control of the disease.
Hear when a new BRAF V600E Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.